Radiopharm Theranostics (RDPTF) Profit After Tax (2023 - 2026)

Radiopharm Theranostics (RDPTF) has reported Profit After Tax for 4 consecutive years, with -$711294.1 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Profit After Tax rose 98.12% year-over-year to -$711294.1 in Q2 2026; TTM through Jun 2026 was -$121.7 million, a N/A change from a year earlier, with the FY2026 full-year figure at $4220.6, down 99.99% from the prior year.
• Profit After Tax was -$711294.1 for Q2 2026 at Radiopharm Theranostics, up from -$37.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$711294.1 in Q2 2026 and troughed at -$47.7 million in Q2 2024.
• A 4-year average of -$30.4 million and a median of -$36.6 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 35.11% in 2024 and soared 98.12% in 2026, its largest moves.
• Over 4 years, Profit After Tax stood at -$35.3 million in 2023, then sank by 35.11% to -$47.7 million in 2024, then gained by 20.67% to -$37.9 million in 2025, then soared by 98.12% to -$711294.1 in 2026.
• The last three Profit After Tax figures came in at -$711294.1 (Q2 2026), -$37.9 million (Q2 2025), and -$47.7 million (Q2 2024), per Business Quant data.